Literature DB >> 2219270

The mechanism of synergistic interaction between anti-interleukin 2 receptor monoclonal antibody and cyclosporine therapy in rat recipients of organ allografts.

H Ueda1, W W Hancock, Y C Cheung, T Diamantstein, N L Tilney, J W Kupiec-Weglinski.   

Abstract

Untreated anephric LEW rats die ca. 9 days following transplantation of LBNF1 kidney allografts. Although treatment with ART-18, a mouse antirat IL-2R mAb (300 micrograms/kg/day x 10 days), prolonged graft survival to ca. 3 weeks, the severely impaired renal function was comparable to untreated controls (creatinine levels 3-5 mg/dl). In contrast, simultaneous infusion of ART-18 and a very low dose of CsA (0.75 mg/kg x 10 days), marginally effective on its own, resulted in survival of greater than 45 days; the grafts exhibited relatively good function comparable to that in rats treated with full-dose (15 mg/kg/day) CsA. This beneficial biological effect did not depend upon elevated CsA trough levels in animals conditioned with both modalities. The CD4:CD8 ratio at the graft site was lowest (0.3-0.4) in recipients treated with ART-18 + CsA. Synergy between the two agents has been demonstrated by adoptive transfer studies in which nonspecific suppression has been conferred selectively by cells infiltrating kidney grafts in rats given ART-18 and CsA in concert but not separately (LBNF1 and WF test cardiac allograft survival ca. 12 days). In contrast, suppression in the recipient spleens was donor-specific; both CD4 and CD8 cells prolonged test graft survival. Immunohistological evaluation of renal allografts revealed that therapy with ART-18 or low-dose CsA alone failed to deplete IL-2R+ cells and prevent production of IL-2, IFN-g, and TNF. In contrast, the frequency of infiltrating IL-2R+ cells and elaboration of endogenous cytokines in non-uremic hosts receiving combination therapy was greatly depressed, stressing again synergistic interaction between ART-18 and CsA. Additionally, markedly reduced class II antigen induction, XL-fibrin deposition, and glomerulitis may also contribute to prolonged survival and satisfactory function of kidney allografts in this animal group.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2219270     DOI: 10.1097/00007890-199010000-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness.

Authors:  R B Landewé; A M Miltenburg; M J Verdonk; C L Verweij; F C Breedveld; M R Daha; B A Dijkmans
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

2.  Long-term kidney isografts develop functional and morphologic changes that mimic those of chronic allograft rejection.

Authors:  S G Tullius; U Heemann; W W Hancock; H Azuma; N L Tilney
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

Review 3.  New strategies in immunosuppression.

Authors:  K I Welsh
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

4.  Therapeutic effect of multiple functional minicircle vector encoding anti-CD25/IL-10/CXCR3 in allograft rejection model.

Authors:  Sun Woo Lim; Yoo Jin Shin; Sheng Cui; Eun Jeong Ko; Seok Ho Yoo; Byung Ha Chung; Chul Woo Yang
Journal:  Korean J Intern Med       Date:  2022-06-21       Impact factor: 3.165

5.  Tumor necrosis factor production during human renal allograft rejection is associated with depression of plasma protein C and free protein S levels and decreased intragraft thrombomodulin expression.

Authors:  A Tsuchida; H Salem; N Thomson; W W Hancock
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.